

Julio Rosenstock

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1592563/julio-rosenstock-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

178
papers

20,033
citations

71
h-index

141
g-index

188
ext. papers

23,897
ext. citations

12.6
avg, IF

6.83
L-index

#	Paper	IF	Citations
178	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 1834-1844	59.2	2547
177	The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. <i>Diabetes Care</i> , 2003 , 26, 3080-6	14.6	1267
176	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). <i>Lancet, The</i> , 2009 , 374, 39-47	40	1178
175	Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. <i>Diabetes Care</i> , 2005 , 28, 1083-91	14.6	1034
174	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 69-79	27.4	562
173	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Clinical Therapeutics</i> , 2006 , 28, 1556-68	3.5	431
172	Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. <i>Diabetes Care</i> , 2015 , 38, 1638-42	14.6	419
171	Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. <i>Annals of Internal Medicine</i> , 2011 , 154, 103-12	8	405
170	Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. <i>Diabetes Care</i> , 2013 , 36, 2508-15	14.6	375
169	Once-Weekly Semaglutide in Adults with Overweight or Obesity. <i>New England Journal of Medicine</i> , 2021 , 384, 989	59.2	351
168	Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. <i>Diabetes Care</i> , 2012 , 35, 1232-8	14.6	339
167	Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. <i>Diabetes Care</i> , 2005 , 28, 950-5	14.6	312
166	Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. <i>Diabetes Care</i> , 2012 , 35, 1473-8	14.6	298
165	Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. <i>Diabetes Care</i> , 2014 , 37, 1815-23	14.6	269
164	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From an EditorsPExpert Forum. <i>Diabetes Care</i> , 2018 , 41, 14-31	14.6	263
163	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. <i>Lancet, The</i> , 2012 , 379, 1498-507	40	259
162	Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. <i>Lancet Diabetes and Endocrinology,the</i> , 2014 , 2, 289-297	18.1	249

161	Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 1155-1166	27.4	245
160	Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. <i>Diabetes Care</i> , 2007 , 30, 217-23	14.6	242
159	Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). <i>Diabetes Care</i> , 2013 , 36, 2489-96	14.6	233
158	Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. <i>Diabetes Care</i> , 2008 , 31, 1479-84	14.6	215
157	Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 1460-1470	27.4	211
156	Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). <i>Diabetes Care</i> , 2013 , 36, 2497-503	14.6	204
155	Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. <i>Diabetes Care</i> , 2015 , 38, 376-83	14.6	202
154	Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). <i>Diabetes Care</i> , 2013 , 36, 2945-51	14.6	193
153	Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. <i>Diabetes Care</i> , 2009 , 32, 1880-6	14.6	193
152	Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. <i>Diabetes Care</i> , 2006 , 29, 554-9	14.6	193
151	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAGliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA ²). <i>Diabetes and Vascular Disease Research</i> , 2015 , 12, 164-74	3.3	182
150	Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial. <i>Diabetes Care</i> , 2015 , 38, 1263-73	14.6	175
149	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 864-876	18.1	174
148	Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. <i>Diabetes Care</i> , 2011 , 34, 2508-14	14.6	174
147	Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. <i>Diabetes Care</i> , 2014 , 37, 2317-25	14.6	173
146	Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. <i>Diabetes Care</i> , 2015 , 38, 412-9	14.6	168
145	Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. <i>Diabetes Care</i> , 2010 , 33, 1173-5	14.6	164
144	Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. <i>Diabetes Care</i> , 2008 , 31, 20-5	14.6	159

143	Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. <i>Diabetes Care</i> , 2016 , 39, 2026-2035	14.6	150
142	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. <i>Diabetes Care</i> , 2018 , 41, 2560-2569	14.6	149
141	Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. <i>Diabetes Care</i> , 2004 , 27, 1265-70	14.6	148
140	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. <i>Diabetes Care</i> , 2016 , 39, 1972-1980	14.6	148
139	Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 1466-1480	27.4	138
138	Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. <i>Diabetes Care</i> , 2015 , 38, 1181-8	14.6	138
137	Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. <i>Diabetes Care</i> , 2008 , 31, 30-5	14.6	135
136	Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. <i>Diabetes Care</i> , 2012 , 35, 1446-54	14.6	133
135	Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. <i>Diabetes Care</i> , 2019 , 42, 2272-2281	14.6	128
134	PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1724-1732	14.6	128
133	Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. <i>Annals of Internal Medicine</i> , 2005 , 143, 549-58 ⁸		120
132	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. <i>Diabetes and Vascular Disease Research</i> , 2013 , 10, 289-301	3.3	119
131	Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. <i>Diabetes Care</i> , 2018 , 41, 1970-1980	14.6	117
130	Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care EditorsPExpert Forum. <i>Diabetes Care</i> , 2013 , 36, 1779-88	14.6	114
129	More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. <i>Diabetes Care</i> , 2018 , 41, 2147-2154	14.6	113
128	Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a 52-week randomized, double-blind study. <i>Diabetes Care</i> , 2013 , 36, 3875-81	14.6	111
127	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017 , 19, 1390-1400	12.3	111
126	Semaglutide 2[4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 971-984	40	109

125	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. <i>Diabetes Care</i> , 2018 , 41, 2552-2559	14.6	109
124	Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 1695-702	5.6	106
123	Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. <i>Diabetes Care</i> , 2004 , 27, 1318-23	14.6	105
122	Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. <i>Diabetes Care</i> , 2016 , 39, 1318-28	14.6	103
121	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. <i>Circulation</i> , 2019 , 139, 351-361	16.7	103
120	Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1414-1425	27.4	102
119	Management of type 2 diabetes in treatment-naïve elderly patients: benefits and risks of vildagliptin monotherapy. <i>Diabetes Care</i> , 2007 , 30, 3017-22	14.6	100
118	SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naïve Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naïve type 2 diabetes. <i>Diabetes Care</i> , 2008 , 31, 2169-76	14.6	93
117	Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. <i>Lancet, The</i> , 2010 , 375, 2244-53	40	92
116	Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 386-92	3.2	90
115	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care EditorsPExpert Forum. <i>Diabetes Care</i> , 2016 , 39, 1186-201	14.6	86
114	Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. <i>Diabetes Care</i> , 2010 , 33, 2406-8	14.6	86
113	Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 353-62	14.6	82
112	Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. <i>Clinical Therapeutics</i> , 2002 , 24, 552-64	3.5	81
111	The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. <i>Diabetes Care</i> , 2013 , 36, 498-504	14.6	80
110	Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2021 , 398, 143-155	40	79
109	Cardiovascular and Renal Outcomes with Epeglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021 , 385, 896-907	59.2	79
108	Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. <i>American Journal of Kidney Diseases</i> , 2015 , 66, 441-9	7.4	75

107	Management of type 2 diabetes mellitus in the elderly: special considerations. <i>Drugs and Aging</i> , 2001 , 18, 31-44	4.7	69
106	Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 393-8	3.2	68
105	Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. <i>Cardiovascular Diabetology</i> , 2015 , 14, 57	8.7	64
104	A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. <i>Diabetes Care</i> , 2007 , 30, 1480-6	14.6	60
103	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. <i>Diabetes Care</i> , 2016 , 39, 1579-86	14.6	59
102	Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. <i>Diabetes Care</i> , 2015 , 38, 431-8	14.6	57
101	Rationale, design, and baseline characteristics of the Cardiovascular safety and Renal Microvascular outcome study with LINAGliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. <i>Cardiovascular Diabetology</i> , 2018 , 17, 39	8.7	57
100	Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2007 , 14, 98-107	4	56
99	Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 1718-28	14.6	56
98	Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. <i>New England Journal of Medicine</i> , 2020 , 383, 2107-2116	59.2	54
97	Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. <i>Diabetes Care</i> , 2017 , 40, 632-639	14.6	53
96	Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. <i>Diabetes Care</i> , 2014 , 37, 2647-59	14.6	48
95	Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naïve type 2 diabetes suboptimally controlled with oral agents. <i>Diabetes Care</i> , 2008 , 31, 2177-82	14.6	45
94	Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. <i>Diabetes Care</i> , 2002 , 25, 1529-33	14.6	41
93	Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1602-1614	6.7	38
92	Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. <i>Diabetes Care</i> , 2019 , 42, 919-930	14.6	37
91	Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36, 2559-65	14.6	37
90	One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. <i>Journal of Diabetes and Its Complications</i> , 2013 , 27, 492-500	3.2	35

89	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. <i>Lancet, The</i> , 2021 , 398, 1811-1824	4.0	35
88	Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. <i>Diabetes Care</i> , 2017 , 40, 839-848	14.6	33
87	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. <i>Diabetes Therapy</i> , 2015 , 6, 289-302	3.6	32
86	Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2019 , 42, 1930-1938	14.6	31
85	Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. <i>Endocrine Practice</i> , 2010 , 16, 617-28	3.2	31
84	Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?. <i>Diabetes Care</i> , 2017 , 40, 1144-1151	14.6	30
83	Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. <i>Endocrine Practice</i> , 2010 , 16, 629-40	3.2	30
82	Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. <i>Diabetes Care</i> , 2018 , 41, 333-340	14.6	30
81	Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial. <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 742-9	3.2	29
80	Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial. <i>Diabetes Technology and Therapeutics</i> , 2009 , 11, 697-705	8.1	29
79	Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2014 , 28, 40-4	3.2	28
78	FDA guidance on antihyperglycemic therapies for type 2 diabetes: One decade later. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1073-1078	6.7	27
77	Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes. <i>Diabetes Care</i> , 2008 , 31, 1723-8	14.6	27
76	Basal insulin supplementation in type 2 diabetes; refining the tactics. <i>American Journal of Medicine</i> , 2004 , 116 Suppl 3A, 10S-16S	2.4	25
75	Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2768-2777	6.7	24
74	Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. <i>Diabetes Care</i> , 2019 , 42, 2108-2116	14.6	23
73	Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 165-172	6.7	22
72	GLYCATED ALBUMIN AT 4 WEEKS CORRELATES WITH A1C LEVELS AT 12 WEEKS AND REFLECTS SHORT-TERM GLUCOSE FLUCTUATIONS. <i>Endocrine Practice</i> , 2015 , 21, 1195-203	3.2	22

71	Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. <i>Diabetes Care</i> , 2015 , 38, 2274-81	14.6	21
70	Diabetes and its complications: blood glucose control vs. genetic susceptibility. <i>Diabetes/metabolism Reviews</i> , 1988 , 4, 417-35		20
69	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2020 , 43, 1803-1812	14.6	20
68	Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2821-2829	6.7	19
67	AIR Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes. <i>Expert Review of Medical Devices</i> , 2007 , 4, 683-92	3.5	19
66	Inhaled insulin: a novel route for insulin delivery. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 687-93	3.9	19
65	Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA: The FREEDOM-1 HBL (High Baseline) Study. <i>Diabetes Care</i> , 2018 , 41, 613-619	14.6	18
64	Novel therapies with precision mechanisms for type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 364-377	15.2	18
63	Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1798-1804	6.7	16
62	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. <i>Circulation</i> , 2020 , 142, 1205-1218	16.7	16
61	Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. <i>Diabetes Care</i> , 2021 , 44, 1586-1594	14.6	16
60	Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial. <i>Diabetes Care</i> , 2018 , 41, 2603-2609	14.6	16
59	Once-Weekly Efglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naïve, Referenced to Liraglutide. <i>Diabetes Care</i> , 2019 , 42, 1733-1741	14.6	15
58	Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2012 , 28, 258-67	7.5	14
57	Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1369-1377	6.7	13
56	Empagliflozin as Add On to Basal Insulin for 78 Weeks Improves Glycemic Control with Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM). <i>Canadian Journal of Diabetes</i> , 2013 , 37, S32	2.1	13
55	Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study. <i>Diabetes Care</i> , 2020 , 43, 161-168	14.6	13
54	Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA trial. <i>Diabetology International</i> , 2020 , 11, 129-141	2.3	13

53	Results of a Study Comparing Glycated Albumin to Other Glycemic Indices. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	13
52	Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA ² trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1062-1073	6.7	12
51	Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. <i>Diabetes Care</i> , 2020 , 43, 2509-2518	14.6	12
50	Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 883-892	6.7	11
49	Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine. <i>Diabetes Technology and Therapeutics</i> , 2009 , 11 Suppl 2, S63-73	8.1	10
48	A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. <i>Diabetes Care</i> , 2021 , 44, 1595-1603	14.6	10
47	Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2152-2162	6.7	9
46	Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1542-1546	6.7	9
45	Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1243-1262	6.7	8
44	Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 318-323	6.7	8
43	Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. <i>Archives of Endocrinology and Metabolism</i> , 2018 , 62, 424-430	2.2	8
42	Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measures. <i>Diabetes Technology and Therapeutics</i> , 2007 , 9, 80-8	8.1	7
41	Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. <i>Circulation</i> , 2021 ,	16.7	7
40	Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 569-580	6.7	7
39	Clinical effects of colesevlam in Hispanic subjects with primary hyperlipidemia and prediabetes. <i>Postgraduate Medicine</i> , 2012 , 124, 14-20	3.7	6
38	Clinical overview of saxagliptin for Type 2 diabetes management. <i>Expert Review of Endocrinology and Metabolism</i> , 2010 , 5, 809-823	4.1	6
37	Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 303-314	6.7	6
36	Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2229-2237	6.7	6

35	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1716-1723	14.6	5
34	Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 diabetes. <i>Diabetes Technology and Therapeutics</i> , 2010 , 12, 185-91	8.1	5
33	Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA trial. <i>Diabetology International</i> , 2021 , 12, 87-100	2.3	5
32	Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2220-2228	6.7	5
31	Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1567-1576	6.7	4
30	Therapy: Gastrointestinal safety of incretin therapies: are we there yet?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 630-632	24.2	4
29	Initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with early type 2 diabetes. <i>Postgraduate Medicine</i> , 2012 , 124, 7-13	3.7	4
28	Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2295-2304	6.7	4
27	Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1221-1231	6.7	4
26	Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?. <i>Diabetes Care</i> , 2021 , 44, 641-646	14.6	4
25	Cardiovascular effects of diabetes drugs: making the dark ages brighter with Carolina. <i>Annals of Internal Medicine</i> , 2013 , 158, 499	8	3
24	Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1445-1452	6.7	3
23	Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1588-1593	6.7	3
22	Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial. <i>Diabetes Care</i> , 2021 ,	14.6	3
21	Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes. <i>Advances in Therapy</i> , 2021 , 38, 1715-1731	4.1	3
20	Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?. <i>Expert Review of Clinical Pharmacology</i> , 2012 , 5, 43-54	3.8	2
19	Basal weekly insulins: the way of the future!. <i>Metabolism: Clinical and Experimental</i> , 2022 , 126, 154924	12.7	2
18	Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 346-354	6.7	2

17	Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 427-433	6.7	2
16	Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2632-2642	6.7	2
15	Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. <i>Diabetes Care</i> , 2021 , 44, 774-780	14.6	2
14	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care EditorsPExpert Forum. <i>Diabetes Care</i> 2016;39:1186-1201. <i>Diabetes Care</i> , 2017 , 40, e23-e24	14.6	1
13	Bringing closure: towards achieving a better understanding of Israel. <i>Lancet, The</i> , 2019 , 394, 559	40	1
12	Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1331-1341	6.7	1
11	191-OR: Similar Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin Naïve or Experienced Patients with T2D. <i>Diabetes</i> , 2021 , 70, 191-OR	0.9	1
10	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 226-236	4.5	1
9	Kidney Effects of Empagliflozin in People with Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1715-1719	6.9	1
8	Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results. <i>Diabetes Therapy</i> , 2021 , 13, 205	3.6	0
7	Response to Comment on Rosenstock and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. <i>Diabetes Care</i> 2015;38:1638-1642. <i>Diabetes Care</i> , 2016 , 39, e139-40	14.6	
6	Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. <i>Diabetes Care</i> 2020;43:2530-2536. <i>Diabetes Care</i> , 2021 , 44, 186-187	14.6	
5	Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin $\geq 8\%$, ≥ 4 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2022 , 24, 34-41	6.7	
4	Treatment of Type 2 Using Insulin 2008 , 69-94		
3	Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021 , 14, 35	3.2	
2	Response to Comment on Ferrannini and Rosenstock. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? <i>Diabetes Care</i> 2021;44:641-646. <i>Diabetes Care</i> , 2021 , 44, e155	14.6	
1	Redefining insulin therapy in type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2004 , 116, 21-9	3.7	